C TWO announces a new executive leadership structure designed to accelerate its ambition to define and lead the emerging category of Universal Orchestration. Paul Donaldson has been appointed Chief ...

The National Council of Educational Research and Training (NCERT), under the Ministry of Education, has launched the e-Magic Box app for children aged 3–8. Featuring three AI-powered bots—Katha Sakhi, ...

GM1 gangliosidosis, caused by biallelic variants in GLB1, results from deficiency of lysosomal β-galactosidase, which degrades GM1 ganglioside. This fatal neurodegenerative disease currently has no ...

Chicago-based Phase 1 Equity has added a multi-site orthodontic practice in Ohio to its network. The deal marks Phase 1 Equity’s first practice partnership of 2026, bringing its network to 26 ...

CMMC Phase 1 officially began on November 10, 2025, but many defense contractors are still unsure if they’re fully ready for it. The confusion is understandable considering the years of delays and ...

Blue Origin’s New Glenn rocket at liftoff during the NG-2 mission on Nov. 13. Credit: Blue Origin The U.S. Space Force is now taking proposals from new launch providers with rockets ready to fly by ...

Fluor and JGC said Monday they had handed over LNG Canada's second production train, bringing the Shell-led project's capacity to 14 million tons a year. Image by MikeMareen via iStock Fluor Corp and ...

Enbridge plans to invest approximately $1.4 billion in the project, adding 150 kbpd of capacity to the Mainline system and 100 kbpd to the FSP. The company expects the new capacity to come online in ...

Angiopoietin-like protein 3 (ANGPTL3) inhibits lipoprotein and endothelial lipases. ANGPTL3 loss-of-function genetic variants are associated with decreased levels of low-density lipoprotein ...

4D-150 demonstrated sustained anti-VEGF delivery, improving visual acuity and reducing supplemental injections in wet AMD patients over 1.5 to 3.5 years. A consistent dose response was observed, ...

PLANO, Texas--(BUSINESS WIRE)--Secretome Therapeutics today announced the launch of a Phase 1, dose-escalating trial of STM-01, Secretome’s neonatal cardiac progenitor cell (nCPC) product, for the ...